Literature DB >> 9636186

Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope.

A Vanderplasschen1, E Mathew, M Hollinshead, R B Sim, G L Smith.   

Abstract

Vaccinia virus (VV) produces two antigenically and structurally distinct infectious virions, intracellular mature virus (IMV) and extracellular enveloped virus (EEV). Here we have investigated the resistance of EEV and IMV to neutralization by complement in the absence of immune antibodies. When EEV is challenged with complement from the same species as the cells used to grow the virus, EEV is resistant to neutralization by complement, whereas IMV is not. EEV resistance was not a result of EEV protein B5R, despite its similarity to proteins of the regulators of complement activation (RCA) family, or to any of the other EEV proteins tested (A34R, A36R, and A56R gene products). EEV was sensitive to complement when the virus was grown in one species and challenged with complement from a different species, suggesting that complement resistance might be mediated by host RCA incorporated into the EEV outer envelope. This hypothesis was confirmed by several observations: (i) immunoblot analysis revealed that cellular membrane proteins CD46, CD55, CD59, CD71, CD81, and major histocompatibility complex class I antigen were detected in purified EEV but not IMV; (ii) immunoelectron microscopy revealed cellular RCA on the surface of EEV retained on the cell surface; and (iii) EEV derived from rat cells expressing the human RCA CD55 or CD55 and CD59 were more resistant to human complement than EEV derived from control rat cells that expressed neither CD55 nor CD59. These data justify further analysis of the roles of these (and possible other) cellular proteins in EEV biology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9636186      PMCID: PMC22678          DOI: 10.1073/pnas.95.13.7544

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

1.  Photochemical inactivation of DNA and RNA viruses by psoralen derivatives.

Authors:  C V Hanson; J L Riggs; E H Lennette
Journal:  J Gen Virol       Date:  1978-08       Impact factor: 3.891

Review 2.  Differences between extracellular and intracellular forms of poxvirus and their implications.

Authors:  E A Boulter; G Appleyard
Journal:  Prog Med Virol       Date:  1973

3.  An antigenic difference between intracellular and extracellular rabbitpox virus.

Authors:  G Appleyard; A J Hapel; E A Boulter
Journal:  J Gen Virol       Date:  1971-10       Impact factor: 3.891

4.  Protection against poxviruses.

Authors:  E A Boulter
Journal:  Proc R Soc Med       Date:  1969-03-03

5.  Biogenesis of poxviruses: role of A-type inclusions and host cell membranes in virus dissemination.

Authors:  Y Ichihashi; S Matsumoto; S Dales
Journal:  Virology       Date:  1971-12       Impact factor: 3.616

6.  Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia.

Authors:  L G Payne
Journal:  J Gen Virol       Date:  1980-09       Impact factor: 3.891

7.  Polypeptide composition of extracellular enveloped vaccinia virus.

Authors:  L Payne
Journal:  J Virol       Date:  1978-07       Impact factor: 5.103

8.  Sensitization of human tumor cells to homologous complement by vaccinia virus treatment.

Authors:  H Okada; N Wakamiya; N Okada; S Kato
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  Presence of haemagglutinin in the envelope of extracellular vaccinia virus particles.

Authors:  L G Payne; E Norrby
Journal:  J Gen Virol       Date:  1976-07       Impact factor: 3.891

10.  Identification of the vaccinia hemagglutinin polypeptide from a cell system yielding large amounts of extracellular enveloped virus.

Authors:  L G Payne
Journal:  J Virol       Date:  1979-07       Impact factor: 5.103

View more
  99 in total

1.  Using confocal microscopy to study virus binding and entry into cells.

Authors:  A Vanderplasschen; G L Smith
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

2.  Golgi network targeting and plasma membrane internalization signals in vaccinia virus B5R envelope protein.

Authors:  B M Ward; B Moss
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein.

Authors:  O Brad Spiller; Mairi Robinson; Elizabeth O'Donnell; Steven Milligan; B Paul Morgan; Andrew J Davison; David J Blackbourn
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  CD59 incorporation protects hepatitis C virus against complement-mediated destruction.

Authors:  Tohti Amet; Marwan Ghabril; Naga Chalasani; Daniel Byrd; Ningjie Hu; Ayslinn Grantham; Ziqing Liu; Xuebin Qin; Johnny J He; Qigui Yu
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

5.  An intravenous stimulus package for oncolytic virotherapy.

Authors:  Richard Vile; Alan Melcher
Journal:  Mol Ther       Date:  2011-11       Impact factor: 11.454

6.  Oncolytic Poxviruses.

Authors:  Winnie M Chan; Grant McFadden
Journal:  Annu Rev Virol       Date:  2014-09-01       Impact factor: 10.431

7.  Species Specificity of Vaccinia Virus Complement Control Protein for the Bovine Classical Pathway Is Governed Primarily by Direct Interaction of Its Acidic Residues with Factor I.

Authors:  Jitendra Kumar; Viveka Nand Yadav; Swastik Phulera; Ashish Kamble; Avneesh Kumar Gautam; Hemendra Singh Panwar; Arvind Sahu
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

8.  Separation of decay-accelerating and cofactor functional activities of Kaposi's sarcoma-associated herpesvirus complement control protein using monoclonal antibodies.

Authors:  Linda Mark; David G Proctor; David J Blackbourn; Anna M Blom; O Brad Spiller
Journal:  Immunology       Date:  2007-08-30       Impact factor: 7.397

9.  Oncolytic vaccinia virotherapy for endometrial cancer.

Authors:  Yu-Ping Liu; Jiahu Wang; Victoria A Avanzato; Jamie N Bakkum-Gamez; Stephen J Russell; John C Bell; Kah-Whye Peng
Journal:  Gynecol Oncol       Date:  2014-01-14       Impact factor: 5.482

10.  Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.

Authors:  Padma Sampath; Jun Li; Weizhou Hou; Hannah Chen; David L Bartlett; Steve H Thorne
Journal:  Mol Ther       Date:  2012-12-11       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.